This post was just published on ZYX Buy Change Alert. Take profits on a 20% tranche of Sumo Logic (SUMO) in the zone of $25 to $27.63. Move stops on a 20% tranche to $23.43 to $23.73. Stops on the remaining 20% in the zone of $21.83 to $21.93. SUMO is trading
This post was just published on ZYX Buy Change Alert. Sumo Logic (SUMO) IPO priced at $22. The opening indication as of this writing is $28 to $29. Consider the following: On a 10% tranche consider taking profits on the open. Consider taking profits on another 10% tranche in the zone of
This post was just published on ZYX Buy Change Alert. Consider taking more partial profits on a 15% tranche on Snowflake (SNOW) in the zone of $214 to $235. SNOW is trading at $226 as of this writing. Yesterday it opened at $245. A knowledgeable investor would have turned $100,000 into
This post was just published on ZYX Buy Change Alert. The new opening indication on SNOW is $225 to $235. What To Do Now Those in the stock may consider taking 10% tranche at the open and profits on another 10% tranche in the zone of $230 to $245. This supersedes the
This post was just published on ZYX Buy Change Alert. The opening indication of Snowflake (SNOW) keeps on rising after the IPO was priced at $120. Please start out by reading the section on Snowflake in the Morning Capsule and the prior post on Snowflake. The latest indication as of this writing
This post was published yesterday in The Arora Report paid services. To gain an edge, this is what you need to know now. Under The Surface On the surface stocks, especially momo stocks, are being aggressively bought. However, under the surface, there is weakness relative to the aggressive buying that occurred in
This post was just published on ZYX Buy Change Alert. Sumo Logic (SUMO) is a new IPO that is likely to start trading this week. The company is a provider of cloud based real time analytics software. This is a call to get up to 70% of the full core position size
This is the golden age of biotech. Huge profits are to be made by astute investors from biotech breakthroughs. One great opportunity for long term investors is Gilead (GILD). Gilead is one of the cheapest large cap biotechs around. Gilead just bought Immunomedics (IMMU). In our analysis, Gilead has the
Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market
This post was just published on ZYX Buy Change Alert. There is a report that SoftBank (SFTBY) is close to selling ARM Holdings to NVIDIA (NVDA). Long time subscribers to The Arora Report may recall making a lot of money from Arora signals on ARM Holdings when it was a public company.